Absolutely not. Who ever said we failed a clinical
Post# of 72440
Quote:
Heading into 2H 2017 we finally catch a glimpse of catalysts that can revive us. With any luck we will have good results in up to four phase 2 trials and possibly even one or more partnerships.
That, of course, is on top of the B-ABSSSI 2b already in the bank. Strong likely hood of excellent results in B-UP and B-OM. Prurisol seem very likely to post decent results with a chance at some truly amazing ones. I'm not sold on the Kevetrin but if The Capital G believes he has something I look forward to finding out if it adds anything to our portfolio.
No where but up when you're face down on the ground.